6503 VV

The global sickle cell disease market is predicted to reach USD 7.9 billion by 2028, with a compound annual growth rate (CAGR) of 7.81 percent. In a report titled “Sickle Cell Disease Market By Treatment Type (Blood Transfusion, Pharmacotherapy, Bone Marrow Transplant), By End User (Hospitals, Diagnostic Centers, Others): Global Industry Perspective, Comprehensive Analysis and Forecast, 2020 – 2028,” Vantage Market Research states that “increasing patient pool, advance therapies, and increasing R&D activities are some of the factors to bolster the market growth.” In 2020, the market was worth USD 1.4 billion.

The following are some of the highlights from the study on Sickle Cell Disease Market:

• Market Assessment • Premium Insights • Competitive Landscape • COVID Impact Analysis • Historic Data, Estimates, and Forecast • Company Profiles • Global and Regional Dynamics

Overview of the Market:

Increasing R&D activity to facilitate rapid market expansion

Increasing R&D effort, a growing patient pool, and a strong pipeline are expected to propel the sickle cell disease market forward over the forecast period. For example, the US Food and Drug Administration approved Voxelotor for the treatment of sickle cell disease. Similarly, Global Blood Therapeutics has been working on development trials for ten medications, including Anti-sicking, HbF inducer, Inclacumab, Voxelotor, and GF1021601, and these drugs are expected to be launched throughout the forecast period, driving the high demand for sickle cell disease.

To have a better understanding of the report’s structure, download a PDF sample copy: @ https://www.vantagemarketresearch.com/industry-report/sickle-cell-disease-diagnosis-market-0209/request-sample

Increased blood transfusions for sickle cell patients are driving up market demand

The market is expected to rise due to an increase in the prevalence of SCD and a high demand for blood transfusions in sickle cell treatment. Blood transfusions aid in the rise of haemoglobin levels in the body by supplementing the regular red blood cell supply. As a result, oxygen supply is improved, and sickle cell obstruction in blood vessels is reduced. This is the cause for the market’s increasing demand for blood transfusions. Plasma transfusion is also beneficial in the treatment of sickle cell disease. As a result, during the projection period, it will fuel the rise of blood transfusion sickle cell treatment.

Regional Analysis: The sickle cell disease market is dominated by North America

North America is expected to dominate the sickle cell disease market as the leading contributor. This is related to prospective pipeline drugs and improved SCD treatment access. The substantial government assistance is a crucial role in the region’s market growth. NHLBI (National Heart, Lung, and Blood Institute) has initiated a collaborative investigation to speed up the development of genetic medicines to cure SCD, according to National Centers for Biotechnological Information.

The following is a list of notable players in the Sickle Cell Disease market:

Alpha Labs, Atlas Medical, BioMedomics Inc, Mayo Clinic, Fisher Scientific, Cigna, ASI, Silver Lake, Research Corporation, LABS Inc.

Request a Business Impact Analysis Prior to and After COVID-19: https://www.vantagemarketresearch.com/insight/press-release/sickle-cell-disease-diagnosis-market-689085

Industry Developments in the Last Few Years:

Novartis AG announced fresh analyses from the two-year positive Phase III JUNIPERA study on November 1, 2021. This study shows how Cosentyx® (secukinumab) treats enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (JPsA), two types of juvenile idiopathic arthritis in children and adolescents (JIA).

2. In October 2021, Novartis AG reported that the FDA had authorised Scemblix® for two indications in chronic myeloid leukaemia (CML).

3. June 2021: Global Blood Therapeutics Inc. announced that the MHRA in the United Kingdom has given Voxelotor a Promising Innovative Medicine (PIM) designation for the possible treatment of haemolytic anaemia in adults and adolescent patients with sickle cell disease aged 12 years and older (SCD).

This research contains information on the prevalence, incidence, patient distribution, average treatment cost, market & technology trends, and new product developments in the sickle cell disease market.

Base Report Attribute Details Forecast for the year 2020 based on historical data from the years 2016 to 2019. Between the years 2021 and 2028, there will be a significant increase in the number of people

• End User o Hospitals o Diagnostic Centers o Others • Treatment Type o Blood Transfusion o Pharmacotherapy o Bone Marrow Transplant
Units for Quantitative Data
USD Millions/Billions in Revenue

Regions North America, Europe, Asia Pacific, Latin America, the Middle East and Africa, and the Rest of the World were all covered. The United States, Canada, Mexico, the United Kingdom, Germany, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Argentina, the Gulf Cooperation Council countries, and South Africa were among the countries covered.

Market growth drivers, restraints, and opportunities, as well as Porter’s five forces analysis, PEST analysis, value chain analysis, regulatory landscape, market attractiveness analysis by segment and region, company market share analysis, and COVID-19 impact analysis, are all covered in this report.

Do you have a question or a specific request? Inquire with one of our industry experts at https://www.vantagemarketresearch.com/industry-report/sickle-cell-disease-diagnosis-market-0209/inquiry-before-buying

Table of Contents – 1st Chapter (Introduction).

1. Report Scope 2. Study Objectives 3. Unique Selling Proposition & Key Offerings
4. Who is your target audience?
5. Guidance/Walkthrough for Vantage Market Research Reports
2. Premium Insights (Chapter 2)
1. Market Overview
2. The Most Profitable Investment Pockets
1. Analysis of market attractiveness by type 2. Analysis of market attractiveness by end user 3. Analysis of market attractiveness by Middle East & Africa
3. Primary Respondents’ Thoughts
3. Key Market Dynamics (Chapter 3)
1. Introduction
2. Market Forces
Market Restraints are the third factor to consider.
4. Business Opportunities
5. Analysis of Porter’s Five Forces
6. Perform a PEST Analysis
7. Regulatory Environment 8. Technology Environment
9. Market Trends in Different Regions

Read Full Report: https://www.vantagemarketresearch.com/industry-report/sickle-cell-disease-diagnosis-market-0209

About the Authors:

Vantage Market Research is a firm dedicated to delivering high-quality data and market research. The firm offers quantitative, high-quality B2B research on over 20,000 emerging markets. The firm provides in-depth reports on a variety of industries, including chemical materials and energy, food and drinks, healthcare, technology, and so on. Every year, the organisation adds more than 1,100 market research papers to its huge database, which employs over 125 analysts and consultants. The company’s customer includes 70% of the Fortune 500 corporations in the world.

Tags: Sickle Cell Disease market, Sickle Cell Disease market 2022, Sickle Cell Disease market sales, Sickle Cell Disease market forecast

See Campaign: https://www.vantagemarketresearch.com/
Contact Information:
Eric Kunz 6218 Georgia Avenue NW Ste 1 – 564 Washington DC 20011-5125 United States Tel: +1 202 380 9727 Email: sales@vantagemarketresearch.com

Reportedtimes, PR-Wirein, Menafn, iCN Internal Distribution, Extended Distribution, Research Newswire, English